These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21211228)

  • 1. [Systematic review of penetrating keratoplasty rejection treated by immunosuppressants].
    Sun YJ; Li AP; Pan ZQ; Luo F; Zou LH
    Zhonghua Yan Ke Za Zhi; 2010 Dec; 46(12):1122-7. PubMed ID: 21211228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Immunosuppressants in High Rejection Risk Keratoplasty: A Meta-Analysis of Comparative Studies.
    Yu K; Lian XF; Jiang XY; Zhou SY
    Cornea; 2021 Jun; 40(6):800-807. PubMed ID: 33941717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The observation of tacrolimus eye drops preventing the early immunological rejection after penetrating keratoplasty for fungal keratitis].
    Xiang DM; Wang YX; Jia YN; Li SX; Zhai HL; Shi WY; Gao H
    Zhonghua Yan Ke Za Zhi; 2017 Apr; 53(4):305-310. PubMed ID: 28412805
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty].
    Xi XH; Qin B; Jiang DY
    Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):627-30. PubMed ID: 15804077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratoplasty postoperative treatment update.
    Shimmura-Tomita M; Shimmura S; Satake Y; Shimazaki-Den S; Omoto M; Tsubota K; Shimazaki J
    Cornea; 2013 Nov; 32 Suppl 1():S60-4. PubMed ID: 24104936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study.
    Qi X; Wang L; Zhang X; Liu M; Gao H
    BMC Ophthalmol; 2022 Mar; 22(1):101. PubMed ID: 35246084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine.
    Yamazoe K; Yamazoe K; Yamaguchi T; Omoto M; Shimazaki J
    Cornea; 2014 Nov; 33(11):1157-63. PubMed ID: 25255133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effectiveness and safety of topical 0.1% tacrolimus after high-risk penetrating keratoplasty].
    Li X; Zhang YN; Yin MY; Pan ZQ
    Zhonghua Yan Ke Za Zhi; 2019 Jun; 55(6):419-427. PubMed ID: 31189271
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A Randomized Controlled Trial.
    Hashemian MN; Latifi G; Ghaffari R; Ghassemi H; Zarei-Ghanavati M; Mohammadi SF; Yasseri M; Fallah Tafti MR; Tafti ZF
    Cornea; 2018 Mar; 37(3):307-312. PubMed ID: 29215395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study.
    Zhai LY; Zhang XR; Liu H; Ma Y; Xu HC
    Eye (Lond); 2020 Sep; 34(9):1600-1607. PubMed ID: 31784702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial.
    Shimazaki J; Tomida D; Yagi-Yaguchi Y; Satake Y; Yamaguchi T
    BMC Ophthalmol; 2024 Jun; 24(1):251. PubMed ID: 38867175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty.
    Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M
    Jpn J Ophthalmol; 2000; 44(3):302-5. PubMed ID: 10913651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty.
    Inoue K; Kimura C; Amano S; Sato T; Fujita N; Kagaya F; Kaji Y; Tsuru T; Araie M
    Jpn J Ophthalmol; 2001; 45(4):378-82. PubMed ID: 11485770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors Affecting Outcomes of Repeated Penetrating Keratoplasty].
    Yamamoto S; Shimmura-Tomita M; Satake Y; Shimazaki-Den S; Shimmura S; Shimazaki J
    Nippon Ganka Gakkai Zasshi; 2015 Sep; 119(9):625-31. PubMed ID: 26477068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study.
    Poon AC; Forbes JE; Dart JK; Subramaniam S; Bunce C; Madison P; Ficker LA; Tuft SJ; Gartry DS; Buckley RJ
    Br J Ophthalmol; 2001 Dec; 85(12):1464-9. PubMed ID: 11734522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
    Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
    Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial.
    Faramarzi A; Abbasi H; Feizi S; Hadi Y; Azari AA; Karimian F; Jafarinasab MR; Kheiri B
    Eye (Lond); 2021 Oct; 35(10):2879-2888. PubMed ID: 33414533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical cyclosporine in pediatric keratoplasty.
    Cosar CB; Laibson PR; Cohen EJ; Rapuano CJ
    Eye Contact Lens; 2003 Apr; 29(2):103-7. PubMed ID: 12695714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
    Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of topical cyclosporine A on keratoplasty rejection in rats].
    Zhang W; Pan Z; Zhai C
    Zhonghua Yan Ke Za Zhi; 2001 Mar; 37(2):140-3. PubMed ID: 11864411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.